The families of two infants who died in the 1960s are suing the federal government alleging the babies received an experimental RSV vaccine without the knowledge or consent of their families, according to a report by The New York Times.
The families of two infants who died in the 1960s are suing the federal government alleging the babies received an experimental RSV vaccine without the knowledge or consent of their families, according to a report by The New York Times.
Read More
Maternal RSV vaccination reduced infants’ hospitalization risk by more than 80% when administered at least 14 days before birth.
Read More
Enanta Pharmaceuticals will present data on its RSV therapy zelicapavir and on EPS-3903, an oral STAT6 inhibitor, at ATS 2026.
Read More
Vertical ventilation ducts in residential buildings can facilitate the spread of infectious respiratory aerosols in multi-family buildings.
Read More
The once-weekly INNA-051 treatment from ENA Respiratory aims to prime the immune system to protect high-risk patients from influenza, RSV, and other respiratory viruses.
Read More
An NFID initiative provided evidence-based guidance on influenza, COVID-19, and RSV during the 2025-2026 season.
Read More
The new Roche diagnostic test identifies 25 viruses and bacteria to help clinicians provide...
Read More
The expanded approval means Arexvy is now indicated for all adults aged 60 and older, and adults aged 18–59 at increased risk for LRTD caused by RSV.
Read More
The American College of Physicians recommends an RSV vaccine for all adults age 75 and older.
Read More
A study found that infant immune systems respond very differently to RSV and SARS-CoV-2, with important treatment implications.
Read More
The 2026 AAP recommendations remain largely unchanged from 2025 but differ from the CDC’s new immunization schedule.
Read More
The Flowflex Plus 4-in-1 is the first single home test FDA-cleared for adults and children 6 months or older to test for RSV, influenza A/B, and COVID-19.
Read More
Recent advances in maternal vaccines and long-acting monoclonal antibodies have broadened the scope of RSV prevention, but questions remain.
Read More
The CDC and HHS reduced the federally recommended childhood immunization schedule from 17 to 11 vaccinations, removing shots for seasonal flu and other infectious diseases.
Read More
For infants in their first RSV season, the monoclonal antibody Nirsevimab (Beyfortus) was 80% effective against RSV-related ICU admission and 83% effective against acute respiratory failure.
Read More
For RSV awareness month (October), the American Lung Association is spotlighting new data that show a dramatic decrease in RSV-related hospitalizations among infants.
Read More
Researchers examined the effectiveness of nirsevimab during the 2024–2025 RSV season using a large, multi-institutional dataset.
Read More
The European Medicines Agency’s CHMP recommended Enflonsia to prevent RSV lower respiratory tract disease in neonates and infants during their first RSV season.
Read More
The AMDI Fast PCR Mini Respiratory Panel is a multiplexed RT-PCR test for the simultaneous detection of Flu A, Flu B, RSV, and SARS-CoV-2 in under 10 minutes.
Read More
One shot of an RSV vaccine protects adults ages 60 or older from RSV-associated hospitalization and critical illness during two consecutive RSV seasons.
Read More
CDC’s annual respiratory disease season outlook predicts similar peak hospitalization rates for COVID-19, influenza and RSV — but a higher hospitalization rate for COVID-19 if a new variant emerges.
Read More
Researchers want to understand why some babies and toddlers get so much sicker from viral infections of flu and RSV.
Read More
The American Academy of Pediatrics published its pediatric immunization recommendations for influenza, RSV, and COVID-19, which differ from some recommendations made by the FDA.
Read More
Beyfortus is a long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Read More
